Opko Health Inc. ( OPK ): Executive VP-Administration Steven D. Rubin bought 2,000 shares
Rubin bought 2,000 shares of OPK stock on Dec. 30 at the average price of $9.18 per share. The price of the stock has increased by 2.18% since.
CEO and chairman Phillip Frost bought 20,000 shares of OPK stock on Jan. 3 at the average price of $9.04 per share. The price of the stock has increased by 3.76% since.
Opko Health is an American pharmaceutical and medication company. The company is mainly focused on diagnostics and pharmaceuticals, but also develops treatments for secondary hyperparathyroidism. In 2014, it acquired Laboratorio Arama de Uruguay. The company has a market cap of $5.23 billion, and as of Jan. 6 the company traded at $9.38.
On Jan. 4, Opko Health's shares dropped more than 20% after a human growth hormone product that it had already licensed to Pfizer failed in late-stage clinical trials. The late-stage study included 203 adult patients with growth hormone deficiency. These patients were split into two groups: one group received a placebo and the other received Opko's growth hormone drug. There was no statistically significant difference between the two patient groups.
Compass Diversified Holdings ( CODI ): Chairman C. Sean Day bought 5,320 shares
Day bought 5,320 shares of CODI stock on Jan. 3 at the average price of $18.16 per share. The price of the stock has decreased by 0.33% since.
Compass Diversified Holdings is an American industrial holdings company whose subsidiaries include Advanced Circuits, American Furniture and Clean Earth. The company has a market cap of $1.08 billion, and as of Jan. 6 it traded at $25.55.
On Jan. 5, Compass Diversifed Holdings announced that its board of directors had declared a quarterly cash distribution of 36 cents per share. The distribution for the quarter ended on Dec. 31, 2016 and is payable on Jan. 26 to all holders of record as of Jan. 19.
Acceleron Pharma Inc. ( XLRN ): Director Joseph S. Zakrzewski bought 4,000 shares
Zakrzewski bought 4,000 shares of XLRN stock on Dec. 30 at the average price of $25.50 per share. The price of the stock has increased by 2.94% since.
SVP, CFO and Treasurer Kevin Mclaughlin sold 1,700 shares of XLRN stock on Jan. 4 at the average price of $27.45 per share. The price of the stock has decreased by 4.37% since.
Acceleron Pharma is an American clinical stage biopharmaceutical company with a focus on developing medicines that target the transformation growth factor beta proteins. The protein family plays an important role in the growth and repair of cells and tissues. The company has a market cap of $990.840 million, and as of Jan. 6 it traded at $26.25.
On Jan. 4, Acceleron Pharma announced that Habib Dable, CEO of the company, will present at the upcoming 35th annual J.P. Morgan Healthcare Conference on Jan. 9. The presentation will include a corporate overview and a review of Acceleron's broad 2017 goals and priorities.
Resolute Energy Corp. ( REN ): Director Gary Hultquist bought 2,000 shares
Hultquist bought 2,000 shares of REN stock on Dec. 30 at the average price of $40.70 per share. The price of the stock has decreased by 0.96% since.
Resolute Energy Corp. is an American oil and gas company that focuses specifically on extracting and refining oil. The company has had significant acquisitions of producing properties and undeveloped areas that support drilling opportunities in 2004 and 2006, which includes its Anneth Field properties in Utah. The company has a market cap of $884.00 million, and as of Jan. 6 it traded at $40.31.
On Dec. 23, 2016, Resolute Energy announced that it has closed its previously announced underwritten public offering of 4.37 million shares of its common stock. This includes the option to purchase an additional 570,000 shares of common stock by underwriters. The net proceeds from the offering were worth approximately $160.8 million.
For the complete list of stocks that were bought by their company executives, go to: Insider Trades.
Disclosure: I do not own stock in any of the companies mentioned in the article.
This article first appeared on GuruFocus .